	US 12,269,877 B2
	Anti-notch3 antibodies
Heidi Okamura, Brookline, MA (US); Sandra Abbott, Boston, MA (US); Alisa C. Bell, Bedford, MA (US); Kelly Kreuter, Arvada, CO (US); Ronan O'Hagan, Arlington, MA (US); Samantha Perino, Brighton, MA (US); Hamid Tissire, Abington, MA (US); William M. Winston, Jr., Marlborough, MA (US); and Jeno Gyuris, Lincoln, MA (US)
Assigned to AVEO Pharmaceuticals, Inc., Boston, MA (US)
Filed by AVEO Pharmaceuticals, Inc., Boston, MA (US)
Filed on Aug. 13, 2020, as Appl. No. 16/992,897.
Application 16/992,897 is a continuation of application No. 15/864,710, filed on Jan. 8, 2018, granted, now 10,745,476.
Application 15/864,710 is a continuation of application No. 14/653,684, granted, now 9,879,083, issued on Jan. 30, 2018, previously published as PCT/US2013/076615, filed on Dec. 19, 2013.
Claims priority of provisional application 61/866,787, filed on Aug. 16, 2013.
Claims priority of provisional application 61/739,435, filed on Dec. 19, 2012.
Prior Publication US 2021/0171627 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 15/09 (2006.01); C12N 15/63 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C12N 5/10 (2006.01); C12N 5/12 (2006.01); C12N 5/16 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 39/3955 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 16/2863 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 5/10 (2013.01); C12N 5/12 (2013.01); C12N 5/16 (2013.01)]

18 Claims

1. A method of inhibiting or reducing ligand-induced Notch3 activity, comprising administering 0.5-20 mg/kg of an anti-Notch3 antibody, or antigen-binding fragment thereof, to a mammal, wherein the anti-Notch3 antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL) selected from the group consisting of:

(a) (i) a VH comprising a CDR_H1comprising the amino acid sequence of SEQ ID NO:51, a CDR_H2comprising the amino acid sequence of SEQ ID NO:53, and a CDR_H3comprising the amino acid sequence of SEQ ID NO:7; and

(ii) a VL comprising a CDR_L1comprising the amino acid sequence of SEQ ID NO:62, a CDR_L2comprising the amino acid sequence of SEQ ID NO:9, and a CDR_L3comprising the amino acid sequence of SEQ ID NO: 10; and

(b) (i) a VH comprising a CDR_H1comprising the amino acid sequence of SEQ ID NO:51, a CDR_H2comprising the amino acid sequence of SEQ ID NO:53, and a CDR_H3comprising the amino acid sequence of SEQ ID NO:7; and

(ii) a VL comprising a CDR_L1comprising the amino acid sequence of SEQ ID NO:64, a CDR_L2comprising the amino acid sequence of SEQ ID NO:9, and a CDR_L3comprising the amino acid sequence of SEQ ID NO: 10.